PharmacyCodes



S-Ropivacaine Mesylate en es it fr

S-Ropivacaine Mesylate Brand names, S-Ropivacaine Mesylate Analogs

S-Ropivacaine Mesylate Brand Names Mixture

  • No information avaliable

S-Ropivacaine Mesylate Chemical_Formula

C4H11N5

S-Ropivacaine Mesylate RX_link

http://www.rxlist.com/cgi/generic4/glumetza.htm

S-Ropivacaine Mesylate fda sheet

S-Ropivacaine_Mesylate FDA

S-Ropivacaine Mesylate msds (material safety sheet)

S-Ropivacaine_Mesylate MSDS

S-Ropivacaine Mesylate Synthesis Reference

No information avaliable

S-Ropivacaine Mesylate Molecular Weight

129.164 g/mol

S-Ropivacaine Mesylate Melting Point

223-226 oC

S-Ropivacaine Mesylate H2O Solubility

Freely soluble as HCl salt

S-Ropivacaine Mesylate State

Solid

S-Ropivacaine Mesylate LogP

-0.267

S-Ropivacaine Mesylate Dosage Forms

Extended release tablet (500 mg or 1000 mg)

S-Ropivacaine Mesylate Indication

For use as an adjunct to diet and exercise to improve glycemic control in adult patients (18 years and older) with type 2 diabetes.

S-Ropivacaine Mesylate Pharmacology

Metformin is an antihyperglycemic agent, which improves glucose tolerance in patients with type 2 diabetes, lowering both basal and postprandial plasma glucose. Metformin is not chemically or pharmacologically related to any other classes of oral antihyperglycemic agents. Unlike sulfonylureas, metformin does not produce hypoglycemia in either patients with type 2 diabetes or normal subjects and does not cause hyperinsulinemia. With metformin therapy, insulin secretion remains unchanged while fasting insulin levels and daylong plasma insulin response may actually decrease.

S-Ropivacaine Mesylate Absorption

Absorbed over 6 hours, bioavailability is 50 to 60% under fasting conditions. Food delays absorption.

S-Ropivacaine Mesylate side effects and Toxicity

Acute oral toxicity (LD50): 350 mg/kg [Rabbit]. It would be expected that adverse reactions of a more intense character including epigastric discomfort, nausea, and vomiting followed by diarrhea, drowsiness, weakness, dizziness, malaise and headache might be seen.

S-Ropivacaine Mesylate Patient Information

S-Ropivacaine Mesylate Organisms Affected

Humans and other mammals